The HIV epidemic continues to pose a major threat to public health. The immunodeficient state caused by HIV infection renders the host highly susceptible to opportunistic pathogens, the latter a major cause of morbidity and mortality in individuals with AIDS. The Albert Einstein College of Medicine (AECOM) provides a rich environment for investigators to conduct HIV and AEDS-related opportunistic pathogens. In vivo animal modeling is essential to research on the pathogenesis, host defense, and treatment of pathogens. Thus, the Biohazard Animal Core, a state-ofthe- art, well-staffed facility that strives to provide a safe, efficient, and cost-effective environment for animal experimentation involving HIV and AIDS-related pathogens, is a critical component of the overall CFAR program. The major goal of the Animal Biohazard Core is to provide CFAR investigators with the technical support and training necessary for successful conduction of bio-hazardous infectious diseases mouse models. As a central program, the Biohazard Animal Core should function to foster sharing of institutional facilities and resources, stimulate scientific exchanges and collaboration, and support career development of young investigators interested in HIV-related research. Based on the progress made in the last funding period, and with AECOM institutional support, as evident by addition of new biohazard containment laboratory space, equipment, as well as salary support for Core personnel, we believe the Biohazard Animal Facility has been successful in executing such functions. We anticipate the CFAR Animal Core to continue to play an important role in facilitating HIV and opportunistic pathogen research at Einstein.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI051519-08
Application #
8058730
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
8
Fiscal Year
2010
Total Cost
$192,953
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Type
DUNS #
110521739
City
Bronx
State
NY
Country
United States
Zip Code
10461
Lankowski, Alexander J; Bien-Gund, Cedric H; Patel, Viraj V et al. (2018) PrEP in the Real World: Predictors of 6-Month Retention in a Diverse Urban Cohort. AIDS Behav :
Kirichenko, Tatiana V; Myasoedova, Veronika A; Shimonova, Tatiana E et al. (2018) Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection. Biosci Rep 38:
Auld, Sara C; Shah, N Sarita; Mathema, Barun et al. (2018) Extensively drug-resistant tuberculosis in South Africa: genomic evidence supporting transmission in communities. Eur Respir J 52:
Harbut, Michael B; Yang, Baiyuan; Liu, Renhe et al. (2018) Small Molecules Targeting Mycobacterium tuberculosis Type II NADH Dehydrogenase Exhibit Antimycobacterial Activity. Angew Chem Int Ed Engl 57:3478-3482
Patel, Viraj V; Dange, Alpana; Rawat, Shruta et al. (2018) Barriers to HIV Testing Among Men Who Have Sex With Men in India Reached Online: Implications for Interventions. J Acquir Immune Defic Syndr 78:e30-e34
Vilchèze, Catherine; Kim, John; Jacobs Jr, William R (2018) Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice. Antimicrob Agents Chemother 62:
Patel, Viraj V; Ginsburg, Zoë; Golub, Sarit A et al. (2018) Empowering With PrEP (E-PrEP), a Peer-Led Social Media-Based Intervention to Facilitate HIV Preexposure Prophylaxis Adoption Among Young Black and Latinx Gay and Bisexual Men: Protocol for a Cluster Randomized Controlled Trial. JMIR Res Protoc 7:e11375
Megra, Bezawit W; Eugenin, Eliseo A; Berman, Joan W (2017) The Role of Shed PrPc in the Neuropathogenesis of HIV Infection. J Immunol 199:224-232
Usyk, Mykhaylo; Zolnik, Christine P; Patel, Hitesh et al. (2017) Novel ITS1 Fungal Primers for Characterization of the Mycobiome. mSphere 2:
Fox, Aaron D; Sohler, Nancy L; Frost, Taeko et al. (2017) Development and evaluation of a community-based buprenorphine treatment intervention. Harm Reduct J 14:23

Showing the most recent 10 out of 531 publications